Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure

A technology for vascular injury and chemotherapy, which can be used in pharmaceutical formulations, peptide/protein components, medical preparations with non-active ingredients, etc., and can solve problems such as serious side effects

Pending Publication Date: 2021-11-16
JANSSEN PHARMA NV
View PDF16 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The simultaneous administration of chemotherapy and radiation therapy can lead to more serious side effects than each therapy alone

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
  • Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
  • Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0133] Embodiment 1(a) is a method of reducing vascular injury in a human subject treated with radiation therapy or chemotherapy, the method comprising administering to the human subject in need thereof an effective amount of thrombopoietin (TPO) mimetic, wherein said TPO mimetic comprises the amino acid sequence of SEQ ID NO: 1, and said effective amount comprises 0.1 microgram (μg) to 6 μg of TPO mimetic per kilogram (kg) of subject body weight, or Fixed or stratified dose equivalents based on typical body weight for the subject population.

[0134] Embodiment 1(b) is a method of promoting organ and / or hematopoietic recovery in a human subject treated with radiation therapy or chemotherapy, the method comprising administering to the human subject in need thereof an effective amount of A thrombopoietin (TPO) mimic, wherein the TPO mimic comprises the amino acid sequence of SEQ ID NO: 1, and the effective amount comprises 0.1 microgram (μg) to 6 μg of the TPO mimic per kilogra...

Embodiment approach 2

[0150] Embodiment 2(h) is the method of embodiment 2, wherein the TPO mimetic is administered to the subject from about 0 minutes to about 32 hours prior to treating the subject with radiation therapy or chemotherapy.

[0151] Embodiment 2(i) is the method of embodiment 2(h), wherein the TPO mimetic is administered to the subject about 10 minutes to about 28 hours before the subject is exposed to radiation therapy or chemotherapy thing.

[0152] Embodiment 2(j) is the method of embodiment 2(h), wherein the TPO mimetic is administered to the subject about 10 minutes to about 24 hours before the subject is exposed to radiation therapy or chemotherapy things.

[0153] Embodiment 2(k) is the method of embodiment 2(h), wherein the TPO mimetic is administered to the subject about 10 minutes to about 20 hours before the subject is exposed to radiation therapy or chemotherapy thing.

[0154] Embodiment 2(l) is the method of embodiment 2(h), wherein the TPO mimetic is administered t...

Embodiment approach 3

[0159] Embodiment 3(a) is a method of reducing vascular injury in a subject treated with radiation therapy or chemotherapy, the method comprising administering to the subject in need thereof an effective amount of thrombopoietin (TPO ) mimetic, wherein the TPO mimetic comprises the amino acid sequence of SEQ ID NO: 1, and is administered to the subject within about 32 hours prior to treating the subject with at least one of radiation therapy and radiomimic chemotherapy The TPO mimetic is administered to the patient.

[0160] Embodiment 3(b) is a method of promoting organ and / or hematopoietic recovery in a subject treated with radiation therapy or chemotherapy, the method comprising administering to the subject in need thereof an effective amount of platelets TPO mimetic, and administering the TPO mimetic to the subject within about 32 hours prior to treating the subject with at least one of radiation therapy and radiation-mimicking chemotherapy.

[0161] Embodiment 3(c) is a ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods of mitigating vascular injury, promoting organ and hematopoietic recovery, accelerating vascular recovery, and enhancing survival in a subject treated with radiation therapy or chemotherapy are described. In particular, an effective amount of a thrombopoietin (TPO) mimetic, such as RWJ-800088, is used at the appropriate times relative to the Total Body Irradiation or Chemotherapy exposure to achieve these prophylactic and / or therapeutic benefits.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Patent Application No. 62 / 796,728 filed January 25, 2019, the disclosure of which is incorporated herein by reference in its entirety. [0003] References to Sequence Listings Submitted Electronically [0004] This application contains a sequence listing, which is electronically submitted through EFS-Web as a sequence listing in ASCII format, with the file name "Sequence Listing of 688097.0960 / 517WO", created on January 23, 2020, and about 3.6kb in size. The sequence listing submitted via EFS-Web is part of this specification and is hereby incorporated by reference in its entirety. [0005] Statement of Government Interest [0006] This invention was made with government support under National Institute of Allergy and Infectious Diseases grant AA112044-001-04000; Defense Medical Research and Development Program JPC-7 project DM178020, and Armed Forces Institute of Radiation ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/10A61P39/00
CPCA61K38/10A61P39/00A61K38/196A61K45/06A61K47/60A61K9/0021
Inventor G·艾肯鲍姆S·高希A·托内利
Owner JANSSEN PHARMA NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com